Research progress of sensitization of chemotherapy and radiotherapy in triple-negative breast cancer

doi:10.12092/j.issn.1009-2501.2019.03.017

Abstract

Abstract:

Triple-negative breast cancer refers to breast cancer with negative expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2). It has the characteristics of poor prognosis, high recurrence rate, rapid invasion and metastasis, and high mortality. Chemotherapy is one of the main means of clinical treatment for triple-negative breast cancer, but with the progress of treatment, triple-negative breast cancer patients are prone to produce different degrees of drug resistance, which greatly reduces the therapeutic effect. Therefore, it is of great importance to find effective targets and preparations for sensitization. This article will review the current status of triple negative breast cancer radiotherapy and chemotherapy, the research progress of known sensitization targets and potential sensitization targets, in order to provide reference for triple negative breast cancer chemotherapy.

Key words: triple-negative breast cancer, chemotherapy, radiotherapy, sensitization

CLC Number:

R737.9

LI Xiaoli，CAI Yongqing，ZHOU Weiying. Research progress of sensitization of chemotherapy and radiotherapy in triple-negative breast cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 337-342.

References

［1］Beiki O, Hall P, Ekbom A, et al. Breast cancer incidence and case fatality among 4.7 million women in relation to social and ethnic background: a population-based cohort study［J］. Breast Cancer Res, 2012, 14(1): R5.
［2］Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence［J］. Clin Cancer Res, 2007, 13(15 Pt 1): 4429-4434.
［3］Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies［J］. J Clin Invest, 2011, 121(7): 2750-2767.
［4］Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy［J］. J Clin Oncol, 2011, 29(21): 2852-2858.
［5］Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer［J］. J Clin Oncol, 2006, 24(36): 5652-5657.
［6］Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer［J］. J Clin Oncol, 2010, 28(7): 1145-1153.
［7］Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial［J］. J Clin Oncol, 2016, 34(3): 244-250.
［8］Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane［J］. J Clin Oncol, 2010, 28(20): 3256-3263.
［9］Twelves C, Cortes J, Vahdat L, et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies［J］. Breast Cancer Res Treat, 2014, 148(3): 553-561.
［10］Doddapaneni R, Patel K, Chowdhury N, et al. Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer［J］. Exp Cell Res, 2016, 346(1): 65-73.
［11］Foygel K, Sekar TV, Paulmurugan R. Monitoring the antioxidant mediatechemosensitization and ARE-signaling in triple negative breast cancer therapy［J］. PLoS One, 2015, 10(11): e0141913.
［12］Robinson P, Kasembeli M, Bharadwaj U, et al. Substance P receptor signaling mediates doxorubicin-induced cardiomyocyte apoptosis and triple-negative breast cancer chemoresistance［J］. Biomed Res Int, 2016, 2016: 1959270.
［13］Thummuri D, Jeengar MK, Shrivastava S, et al. Boswellia ovalifoliolata abrogates ROS mediated NF-κB activation, causes apoptosis and chemosensitization in triple negative breast cancer cells［J］. Environ Toxicol Pharmacol, 2014, 38(1): 58-70.
［14］Her S, Cui L, Bristow RG, et al. Dual action enhancement of gold nanoparticle radiosensitization by pentamidine in triple negative breast cancer［J］. Radiat Res, 2016, 185(5): 549-562.
［15］Tseng D, Vasquez-Medano DA, Brown JM. Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas［J］. Br J Cancer, 2011, 104(12): 1805-1809.
［16］唐心宇，曹远东，孙新臣. CXCL12 受体抑制剂调控三阴性乳腺癌放射治疗的敏感性［J］. 临床肿瘤学杂志, 2017, 22(11): 973-977.
［17］Wong-Brown MW, Meldrum CJ, Carpenter JE, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer［J］. Breast Cancer Res Treat, 2015, 150(1): 71-80.
［18］Comen EA, Robson M. Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer［J］. Oncology, 2010, 24(1): 55-62.
［19］Gelmon KA, Hirte HW, Robidoux A, et al. Can we define tumors that will respond to PARP inhibitors-A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer［J］. J Clin Oncol, 2010, 28(15): 3002.
［20］Jang NY, Kim DH, Cho BJ, et al. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer［J］. BMC Cancer, 2015, 15: 89.
［21］Ouyang M, Li Y, Ye S, et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer［J］. PLoS One, 2014, 9(5): e96228.
［22］Li HY, Liang JL, Kuo YL, et al. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer［J］. Breast Cancer Res, 2017, 19(1): 133.
［23］Das S. Identification and targeting of microRNAs modulating acquired chemotherapy resistance in Triple negative breast cancer (TNBC): A better strategy to combat chemoresistance［J］. Med Hypotheses, 2016, 96: 5-8.
［24］Bousquet G, El Bouchtaoui M, Sophie T, et al. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer［J］. Oncotarget, 2017, 8(21): 35205-35221.
［25］Moreira MP, da Conceicao Braga L, Cassali GD, et al. STAT3 as a promising chemoresistance biomarker associated with the CD44+/high/CD24-/low/ALDH+ BCSCs-like subset of the triple-negativebreast cancer (TNBC) cell line［J］. Exp Cell Res, 2018, 363(2): 283-290.
［26］Soleymani Abyaneh H, Gupta N, Radziwon-Balicka A, et al. STAT3 but not HIF-1α is important in mediating hypoxia-induced chemoresistance in MDA-MB-231, a triple negative breast cancer cell line［J］. Cancers (Basel), 2017, 9(10):137.
［27］Singel SM, Cornelius C, Zaganjor E, et al. KIF14 promotes AKT phosphorylation and contributes tochemoresistance in triple-negative breast cancer［J］. Neoplasia, 2014, 16(3): 247-56, 256.e2.
［28］周维英. 肿瘤研究的新焦点--外体［J］. 第三军医大学学报, 2016, 38(1): 1-7.
［29］Ciravolo V, Huber V, Ghedini GC, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy［J］. J Cell Physiol, 2012, 227(2): 658-667.
［30］Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRv III by microvesicles derived from tumour cells［J］. Nat Cell Biol, 2008, 10(5): 619-624.
［31］Safaei R, Larson BJ, Cheng TC, et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells［J］. Mol Cancer Ther, 2005, 4(10): 1595-1604.
［32］Xu W, Luo T, Li P, et al. RGD-conjugated gold nanorods induce radiosensitization in melanoma cancer cells by downregulating αvβ3 expressionI［J］. Int J Nanomedicine, 2012, 7: 915-924.
［33］Hall H, Hubbell JA. Matrix-bound sixth Ig-like domain of cell adhesion molecule L1 acts as an angiogenic factor by ligating αvβ3-integrin and activating VEGF-R2［J］. Microvasc Res, 2004, 68(3): 169-178.
［34］Chu QD, Panu L, Holm NT, et al. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome［J］. J Surg Res, 2010, 159(2): 689-695.
［35］Li P, Zhang Q, Torossian A, et al. Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer［J］. Int J Radiat Oncol Bio Phys, 2012, 83(3): e391-397.
［36］Rahimi M, George J, Tang C. EGFR variant mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms［J］. Int J Cancer, 2010, 126(8): 1850-1860.
［37］Speers C, Zhao SG, Chandler B, et al. Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer［J］. NPJ Breast Cancer, 2017, 3:29.

[1]	WANG Ruyue, XIE Fei, WANG Xin, LI Hongyu. Therapeutic effect of lienal polypeptide injection on bone marrow suppression and immunodeficiency in KM mice following chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1000-1007.
[2]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[3]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[4]	LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao. Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593.
[5]	WU Rongrong, CHEN Zhiqiang, JIA Yifei, CHEN Hongqi, WANG Panpan, YAN Ru. Applications of BGUSs inhibition in tumor prevention and chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 964-974.
[6]	ZHAO Quanfeng, FU Peishu, GU Wenrui, ZHEN Dan, LV Zongjie, YANG Yang. Advances in evidence-based medical research of GnRHa for fertility protection after chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1449-1454.
[7]	TIAN Yali, FENG Lin, ZHAO Wan, GU Min, SHEN Hanjing, CHAI Xiaoyan. Correlation of BRCA1 gene polymorphism with chemosensitivity and prognosis of metastatic esophageal squamous cell carcinoma treated with cisplatin combined with capecitabine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1118-1126.
[8]	ZHANG Dezhi, LIU Meng, ZHU Shaogong, LIU Guiju, JI Jie. Efficacy and safety of XELOX therapy in comparison with capecitabine monotherapy in adjuvant chemotherapy for elderly patients with colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 926-936.
[9]	TANG Mufei, SHEN Yunzhu, ZHANG Baoguo. Influence of CYP2D6 gene polymorphism on the effect of tropisetron in preventing chemotherapy induced nausea and vomiting [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 817-822.
[10]	ZHAO Miaohui, ZHOU Jiani, QI Yong. Mulberry polysaccharides improves the chemotherapy of liver cancer ascites tumor-bearing mice by regulating the PI3K/AKT/mTOR pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 401-407.
[11]	WANG Aijuan, GUO Yiyun, WANG Zhiqiu. Apatinib combined with capecitabine in the treatment of advanced triple-negative breast cancer as third-line therapy: An observational study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 433-439.
[12]	ZHAO Quanming, YANG Yang. Progress in drug therapy for advanced triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 475-480.
[13]	PAN Luping, SHI Wujie, SHEN Zhipeng. Efficacy and safety of etoposide combined with carboplatin in children with recurrent medulloblastoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 189-195.
[14]	XU Weiping, ZHOU Weiying. Advances in the sensitization mechanism of chemotherapeutic drugs for bladder cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1060-1064.
[15]	LI Rongzhen, MEI Jiazhuan, XIA Yunzhan, JI Jie. Prognostic factors and safety study of R0 resection colorectal cancer patients received capecitabine based adjuvant chemotherapy in real world [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 704-711.